Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-12-18

FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for MAXITROL, a combination ophthalmic solution containing neomycin sulfate, polymyxin B sulfate and dexamethasone, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MAXITROL (Neomycin sulfate, polymyxin B sulfate and dexamethasone; neomycin and polymyxin B sulfates and dexamethasone)

Snippet

SUPPL AP for MAXITROL (NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND DEXAMETHASONE)